---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-108868"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:15:25.487903+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences Q2 net loss $2.1M; TA-ERT BLA for MPS IIIB on track Q1 2026

## Summary
- Net loss of $2.1M for Q2 2025 vs $9.2M in Q2 2024; cash $16.4M expected to fund through end of 2025.
- Integrated TA-ERT data shows CSF HS-NRE reduced 91.5 ng/mL at 240 weeks (p<0.0001); cognition stabilized vs decline in untreated.
- First patient dosed in Phase 2 TAMARIND trial of tildacerfont for MDD; topline results expected 1H 2026.
- BLA submission for TA-ERT under accelerated approval pathway anticipated Q1 2026; potential first disease-modifying therapy for MPS IIIB.
- Nasdaq relisting expected after maintaining minimum bid price for 20 consecutive trading days following 1-for-75 reverse stock split.

## SEC filing metadata
- accession: 0000950170-25-108868
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000095017025108868/0000950170-25-108868-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000095017025108868/sprb-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-108868
- JSON: https://secwatch.observer/filing/0000950170-25-108868.json
- Plain text: https://secwatch.observer/filing/0000950170-25-108868.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.